NASDAQ
0.67USD
-0.02 (-2.52%)
We have scored 5 news catalysts on KALA BIO, Inc. (KALA) over the past 12 months. The biggest single-day move next to one of them came Feb 8, 2026, when KALA closed +10.3%: “KALA BIO, Inc. (NASDAQ:KALA) Receives $20.38 Average Price Target from Brokerages”. Coverage across the window leans positive (average ticker sentiment +0.18). Most of the impact sits in short squeeze potential and price momentum.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Latest scored catalyst for KALA: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Market cap
13M
P/E
—
EPS
—
Beta
-2.28
52W range
0.587-1030
Day range
0.66–0.76
Open
0.67
Prev close
0.69
Volume
238.2K
Avg volume
146.3K
Dividend
0.00
IPO
2017-07-20
Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions. The core of their strategy involves utilizing proprietary nanoparticle technology, specifically mucus penetrating particles (MPPs). Initially, their focus for these treatments is directed towards ophthalmic diseases. The company was established in 2009 by co-founders Justin Hanes, Robert S. Langer, and Colin R. Gardner, and its headquarters are located in Arlington, Massachusetts.
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about KALA BIO, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
